163 related articles for article (PubMed ID: 37325945)
1. Comparison of tyrosine kinase inhibitors in the treatment of metastatic renal cell carcinoma with rhabdoid and sarcomatoid differentiations.
Wang K; Duan P; Chen X; Yang Q; Feng G; Diao L; Zhang Z; Yao X
Cancer Med; 2023 Jul; 12(13):14149-14156. PubMed ID: 37325945
[TBL] [Abstract][Full Text] [Related]
2. Cytoreductive Nephrectomy for Patients with Metastatic Sarcomatoid and/or Rhabdoid Renal Cell Carcinoma Treated with Immune Checkpoint Therapy.
Hahn AW; Kotecha RR; Viscuse PV; Pieretti AC; Wiele AJ; Jonasch E; Lee CH; Gao J; Zurita AJ; Shah AY; Campbell MT; Sharma P; Motzer RJ; Russo P; Wood CG; Tannir NM; Voss MH; Karam JA; Hakimi AA; Msaouel P
Eur Urol Focus; 2023 Sep; 9(5):734-741. PubMed ID: 36863962
[TBL] [Abstract][Full Text] [Related]
3. Prognostic implications of sarcomatoid and rhabdoid differentiation in patients with grade 4 renal cell carcinoma.
Kara O; Maurice MJ; Zargar H; Malkoc E; Akca O; Andrade HS; Ramirez D; Caputo PA; Nelson RJ; Rini B; Kaouk JH
Int Urol Nephrol; 2016 Aug; 48(8):1253-1260. PubMed ID: 27215555
[TBL] [Abstract][Full Text] [Related]
4. Impact of sarcomatoid differentiation and rhabdoid differentiation on prognosis for renal cell carcinoma with vena caval tumour thrombus treated surgically.
Yang B; Xia H; Xu C; Lu M; Zhang S; Wang G; Ma L
BMC Urol; 2020 Feb; 20(1):14. PubMed ID: 32070319
[TBL] [Abstract][Full Text] [Related]
5. Early Tumor Shrinkage Under Treatment with First-line Tyrosine Kinase Inhibitors as a Predictor of Overall Survival in Patients with Metastatic Renal Cell Carcinoma: a Retrospective Multi-Institutional Study in Japan.
Miyake H; Miyazaki A; Imai S; Harada K; Fujisawa M
Target Oncol; 2016 Apr; 11(2):175-82. PubMed ID: 26341668
[TBL] [Abstract][Full Text] [Related]
6. Spine stereotactic radiosurgery with concurrent tyrosine kinase inhibitors for metastatic renal cell carcinoma.
Miller JA; Balagamwala EH; Angelov L; Suh JH; Rini B; Garcia JA; Ahluwalia M; Chao ST
J Neurosurg Spine; 2016 Dec; 25(6):766-774. PubMed ID: 27391397
[TBL] [Abstract][Full Text] [Related]
7. Treatments, Outcomes, and Validity of Prognostic Scores in Patients With Sarcomatoid Renal Cell Carcinoma: A 20-Year Single-Institution Experience.
Korenbaum C; Pierard L; Thiéry A; Story F; Lindner V; Lang H; Kurtz JE; Barthélémy P
Clin Genitourin Cancer; 2018 Jun; 16(3):e577-e586. PubMed ID: 29395949
[TBL] [Abstract][Full Text] [Related]
8. Sarcomatoid dedifferentiation in metastatic clear cell renal cell carcinoma and outcome on treatment with anti-vascular endothelial growth factor receptor tyrosine kinase inhibitors: a retrospective analysis.
Beuselinck B; Lerut E; Wolter P; Dumez H; Berkers J; Van Poppel H; Joniau S; Oyen R; De Wever L; Strijbos M; Paridaens R; Schöffski P
Clin Genitourin Cancer; 2014 Oct; 12(5):e205-14. PubMed ID: 24861951
[TBL] [Abstract][Full Text] [Related]
9. Significance of preoperative prognostic nutrition index as prognostic predictors in patients with metastatic renal cell carcinoma with tyrosine kinase inhibitors as first-line target therapy.
Cai W; Zhong H; Kong W; Dong B; Chen Y; Zhou L; Xue W; Huang Y; Zhang J; Huang J
Int Urol Nephrol; 2017 Nov; 49(11):1955-1963. PubMed ID: 28889323
[TBL] [Abstract][Full Text] [Related]
10. Presence of sarcomatoid differentiation as a prognostic indicator for survival in surgically treated metastatic renal cell carcinoma.
Gu L; Li H; Wang H; Ma X; Wang L; Chen L; Zhao W; Zhang Y; Zhang X
J Cancer Res Clin Oncol; 2017 Mar; 143(3):499-508. PubMed ID: 27844145
[TBL] [Abstract][Full Text] [Related]
11. The relationship between systemic immune inflammation index and survival in patients with metastatic renal cell carcinomatreated withtyrosine kinase inhibitors.
Yücel KB; Yekedüz E; Karakaya S; Tural D; Ertürk İ; Erol C; Ercelep Ö; Öztaş NŞ; Arslan Ç; Uçar G; Küçükarda A; Sever ÖN; Kılıçkap S; Can O; Yazgan SC; Öksüzoğlu B; Karadurmuş N; Şendur MA; Ürün Y
Sci Rep; 2022 Oct; 12(1):16559. PubMed ID: 36192500
[TBL] [Abstract][Full Text] [Related]
12. Cabozantinib in the treatment of metastatic renal cell carcinoma - final data analysis from four oncology centers in the Czech Republic.
Richter I; Poprach A; Zemánková A; Büchler T; Bartoš J; Šámal V; Študentová H; Rozsypalová A; Dvořák J; Brom O; Melichar B
Klin Onkol; 2021; 34(5):392-400. PubMed ID: 34915708
[TBL] [Abstract][Full Text] [Related]
13. [Comparison of efficacy between sorafenib and sunitinib as first-line therapy for metastatic renal cell carcinoma and analyze prognostic factors for survival].
Cai W; Yuan YC; Li MY; Kong W; Dong BJ; Chen YH; Zhang J; Xue W; Huang YR; Zhou LX; Huang JW
Zhonghua Zhong Liu Za Zhi; 2018 May; 40(5):384-389. PubMed ID: 29860767
[No Abstract] [Full Text] [Related]
14. Impact of Rhabdoid Differentiation on Prognosis for Patients with Grade 4 Renal Cell Carcinoma.
Zhang BY; Cheville JC; Thompson RH; Lohse CM; Boorjian SA; Leibovich BC; Costello BA
Eur Urol; 2015 Jul; 68(1):5-7. PubMed ID: 25638439
[TBL] [Abstract][Full Text] [Related]
15. Synchronous Versus Metachronous Metastatic Disease: Impact of Time to Metastasis on Patient Outcome-Results from the International Metastatic Renal Cell Carcinoma Database Consortium.
Donskov F; Xie W; Overby A; Wells JC; Fraccon AP; Sacco CS; Porta C; Stukalin I; Lee JL; Koutsoukos K; Yuasa T; Davis ID; Pezaro C; Kanesvaran R; Bjarnason GA; Sim HW; Rathi N; Kollmannsberger CK; Canil CM; Choueiri TK; Heng DYC
Eur Urol Oncol; 2020 Aug; 3(4):530-539. PubMed ID: 32037304
[TBL] [Abstract][Full Text] [Related]
16. Novel risk scoring system for metastatic renal cell carcinoma patients treated with cabozantinib.
Martini DJ; Kline MR; Liu Y; Shabto JM; Carthon BC; Russler GA; Yantorni L; Hitron EE; Caulfield S; Goldman JM; Harris WB; Kucuk O; Master VA; Bilen MA
Cancer Treat Res Commun; 2021; 28():100393. PubMed ID: 34029879
[TBL] [Abstract][Full Text] [Related]
17. Association of post-treatment hypoalbuminemia and survival in Chinese patients with metastatic renal cell carcinoma.
Cai W; Zhang J; Chen Y; Kong W; Huang Y; Huang J; Zhou L
Chin J Cancer; 2017 May; 36(1):47. PubMed ID: 28521783
[TBL] [Abstract][Full Text] [Related]
18. Absence of Significant Correlation of Adverse Events Between First- and Second-Line Tyrosine Kinase Inhibitors in Patients With Metastatic Renal Cell Carcinoma.
Miyake H; Imai S; Harada K; Fujisawa M
Clin Genitourin Cancer; 2016 Feb; 14(1):e19-24. PubMed ID: 26382221
[TBL] [Abstract][Full Text] [Related]
19. Treatment and Outcome of Metastatic Renal Cell Carcinoma With Sarcomatoid Differentiation: A Single-Center, Real-World Analysis of Retrospective Data.
Janisch F; Kienapfel C; Fühner C; Klotzbücher T; Marks P; Hillemacher T; Meyer CP; Iwata T; Parizi MK; Sauter G; Fisch M; Shariat SF; Dahlem R; Rink M
Front Surg; 2021; 8():763271. PubMed ID: 34869564
[No Abstract] [Full Text] [Related]
20. Cabozantinib in Patients with Advanced Renal Cell Carcinoma Primary Refractory to First-line Immunocombinations or Tyrosine Kinase Inhibitors.
Santoni M; Massari F; Bracarda S; Grande E; Matrana MR; Rizzo M; De Giorgi U; Basso U; Aurilio G; Incorvaia L; Martignetti A; Molina-Cerrillo J; Mollica V; Rizzo A; Battelli N
Eur Urol Focus; 2022 Nov; 8(6):1696-1702. PubMed ID: 35193819
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
